1. Ebola Virus Transmission Initiated by Relapse of Systemic Ebola Virus Disease
- Author
-
Karthik Gangavarapu, Amuri Aziza, Ibrahima Socé Fall, Marceline Akonga, Anne W. Rimion, Yannick Tutu Tshia N’kasar, Moussa Moïse Diagne, Fabrice Mambu, Jean Jacques Muyembe Tamfum, Ali Torkamani, Meris Matondo, Daniel Mukadi, Nancy J. Sullivan, Nella Bisento, Antoine Nkuba-Ndaye, Abdoulaye Yam, Emilia Sana-Paka, Elias Salfati, Kristian G. Andersen, Placide Mbala-Kingebeni, Bibiche Nsunda, Bailey White, Martin Faye, Francois Edidi, John Misasi, Marc A. Suchard, Michael R. Wiley, Boubacar Diallo, Catherine Pratt, Faustin Bile, Aurélie Ploquin, Olivier Tshiani, Matthias Pauthner, Steve Ahuka-Mundeke, Sabue Mulangu, Allison Black, Eddy Kinganda-Lusamaki, Amadou A. Sall, Ousmane Faye, Mbusa Mutafali-Ruffin, Lisa E. Hensley, Trevor Bedford, Marie Roseline Darnycka Belizaire, Victor Epaso, Ian Crozier, Donatien Kazadi, James Hadfield, Andrew Rambaut, Mory Keita, and Junior Bula Bula
- Subjects
Male ,Fatal outcome ,viruses ,Disease ,030204 cardiovascular system & hematology ,medicine.disease_cause ,Medical and Health Sciences ,Fatal Outcome ,0302 clinical medicine ,Recurrence ,Viral ,030212 general & internal medicine ,Phylogeny ,Genome ,biology ,Transmission (medicine) ,General Medicine ,Ebolavirus ,Infectious Diseases ,Vesicular stomatitis virus ,Ebola ,Democratic Republic of the Congo ,Infection ,Biotechnology ,Adult ,Viremia ,Vaccine Related ,03 medical and health sciences ,Rare Diseases ,Biodefense ,General & Internal Medicine ,medicine ,Humans ,Ebola Vaccines ,Ebola virus ,Extramural ,business.industry ,Prevention ,Outbreak ,Bayes Theorem ,biology.organism_classification ,medicine.disease ,Virology ,Emerging Infectious Diseases ,Good Health and Well Being ,Mutation ,Hemorrhagic Fever ,RNA ,Immunization ,business - Abstract
During the 2018-2020 Ebola virus disease (EVD) outbreak in North Kivu province in the Democratic Republic of Congo, EVD was diagnosed in a patient who had received the recombinant vesicular stomatitis virus-based vaccine expressing a ZEBOV glycoprotein (rVSV-ZEBOV) (Merck). His treatment included an Ebola virus (EBOV)-specific monoclonal antibody (mAb114), and he recovered within 14 days. However, 6 months later, he presented again with severe EVD-like illness and EBOV viremia, and he died. We initiated epidemiologic and genomic investigations that showed that the patient had had a relapse of acute EVD that led to a transmission chain resulting in 91 cases across six health zones over 4 months. (Funded by the Bill and Melinda Gates Foundation and others.).
- Published
- 2021
- Full Text
- View/download PDF